French medtech Volta Medical snaps €36M to detect and prevent cardiac diseases using AI -- TFN

Volta Medical, a France-based health technology company developing AI solutions to assist electrophysiologist physicians and surgeons, has secured €36 million in Series B funding. With this, the total funding raised by the company accounts for €70 million. The investment round was led by the US-based Vensana Capital alongside participation from Lightstone Ventures (which backed Dunzo and Nimbus Therapeutics) and existing investor Gilde Healthcare. The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialisation, and pursue further regulatory approvals. The company's lead product, VOLTA VX1, is the first commercially available AI decision-support software to help guide physicians with identification and real-time annotation of unique abnormalities on 3D anatomical and electrical maps of the heart.